Applied Genetic Technologies Corp (NASDAQ:AGTC) Receives Average Rating of “Buy” from Brokerages
Applied Genetic Technologies Corp (NASDAQ:AGTC) has earned an average rating of “Buy” from the nine ratings firms that are currently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $10.58.
Several equities research analysts recently issued reports on the company. Chardan Capital raised Applied Genetic Technologies from a “neutral” rating to a “buy” rating and set a $7.50 price objective for the company in a research note on Tuesday, September 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Applied Genetic Technologies in a research report on Thursday, July 25th. Zacks Investment Research lowered Applied Genetic Technologies from a “buy” rating to a “hold” rating in a research report on Monday, August 12th. Janney Montgomery Scott initiated coverage on Applied Genetic Technologies in a research report on Friday, September 6th. They issued a “buy” rating and a $13.00 target price on the stock. Finally, ValuEngine raised Applied Genetic Technologies from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st.
Applied Genetic Technologies stock traded down $0.05 during mid-day trading on Friday, hitting $3.68. The company’s stock had a trading volume of 128,201 shares, compared to its average volume of 109,492. The firm’s 50 day moving average is $3.48 and its 200 day moving average is $3.90. The company has a market cap of $67.78 million, a PE ratio of 37.30 and a beta of 2.55. Applied Genetic Technologies has a 52-week low of $2.26 and a 52-week high of $7.50.
Applied Genetic Technologies Company Profile
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology.
Featured Article: How a Strangle Strategy is different from a Straddle Strategy
Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.